Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 778-780

  Hillman, Sarah ^a,c   Chant, Ian ^b   Gu, Mei ^a   Rose, Peter ^b,c   Vatish, Manu ^a,c,d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b WARWICK HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; HYPERCOAGULABILITY; LETTER; MAJOR CLINICAL STUDY; MEDICAL ETHICS; PREDICTION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SCANNING ELECTRON MICROSCOPY; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; LIPOPROTEINS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 64849086367     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0633     Document Type: Letter

References (14)

1. Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-972.
2. Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103:3106-3111.
3. Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-470.
4. Bai H, Ma D, Zhang Y, et al Molecular design and characterization of recombinant long half-life mutants of human tissue factor pathway inhibiton. Thromb Haemost 2005; 93: 1055-1060.
5. Vinnars MT, Wijnaendts LC, Westgren M, et al. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008; 51: 1295-1299.
6. Kobayashi T, Tokunaga N, Sugimura M, et al. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999; 25: 451-454.
7. Tanjung MT, Siddik HD, Hariman H, et al. Coagulation and fibrinolysis in preeclampsia and neonates. ClinAppl Thromb Hemost 2005; 11:467-473.
8. Halligan A, Bonnar J, Sheppard B, et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101:488-492.
9. Abdel Gader AM, Al-Mishari AA, Awadalla SA, et al. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006; 95:248-253.
10. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892-898.
11. Unal ER, Robinson CJ, Johnson DD, et al. Secondtrimester angiogenic factors as biomarkers for futureonset preeclampsia. Am J Obstet Gynecol 2007; 197: 211.
12. Polliotti BM, Fry AG, Sailer DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-1274.
13. Powers RW, Roberts JM, Cooper KM, et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185-191.
14. Dusse LM, Carvalho MG, Getliffe K, et al. Total plasma tissue factor pathway inhibitor levels in preeclampsia. Clin Chim Acta 2008 ; 388: 230-232.